Related Experiment Video

Updated: Aug 15, 2026

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
11:49

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

Published on: April 3, 2026

Does neoadjuvant/adjuvant chemotherapy change the natural history of classic invasive lobular carcinoma?

Artur Katz

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |September 20, 2005
    PubMed
    Abstract

    No abstract available in PubMed .

    Related Experiment Videos

    Last Updated: Aug 15, 2026

    Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
    11:49

    Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

    Published on: April 3, 2026

    Related Concept Videos

    Tumor Progression02:07

    Tumor Progression

    Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
    Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

    Articles linked to this work by shared authors, journal, and citation graph.

    Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR+/HER2-Negative Breast Cancer: A Real-World Study.

    Cancer medicine·2026

    Control of Intraocular Metastases of ALK-Rearranged Non-Small Cell Lung Cancer with Sequential Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Report of 2 Cases and Review of the Literature.

    Case reports in oncology·2026

    Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520).

    JCO oncology practice·2026

    Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.

    Journal for immunotherapy of cancer·2025

    Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study.

    Breast (Edinburgh, Scotland)·2025

    Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.

    Journal for immunotherapy of cancer·2025

    Development and Validation of a Blood Test Informed Risk Prediction Model for Lung Cancer-The Copenhagen Lung Cancer Risk Model (CPH-Lung).

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505).

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Phase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Prognostic Impact of Telomere Maintenance Mechanisms in Neuroblastoma.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us